CVA Family Office’s Veracyte VCYT Stock Holding History

CVA Family Office’s Portfolio VCYT Stock Details VCYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$870	Buy	27 +3	+13%	+$111	﹤0.01%	1674
2025 Q4	$1.01K	Hold	24	–	–	﹤0.01%	1099
2025 Q3	$824	Hold	24	–	–	﹤0.01%	1157
2025 Q2	$649	Hold	24	–	–	﹤0.01%	1169
2025 Q1	$712	Hold	24	–	–	﹤0.01%	1165
2024 Q4	$950	Hold	24	–	–	﹤0.01%	1103
2024 Q3	$817	Hold	24	–	–	﹤0.01%	1106
2024 Q2	$520	Buy	+24	New	+$505	﹤0.01%	1191

Other funds holding VCYT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CVA Family Office's VCYT Position: Q1 2026 in Review

CVA Family Office increased its Veracyte (VCYT) stake by 13% in Q1 2026, buying an estimated $111 and bringing the position to 27 shares worth $870. The position accounts for ﹤0.01% of the portfolio, ranked #1674.

CVA Family Office first reported a position in VCYT in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.01K in Q4 2025. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

CVA Family Office held 27 shares of Veracyte worth $870 as of Q1 2026.
CVA Family Office bought 3 Veracyte shares in Q1 2026, an estimated $111.
Veracyte made up ﹤0.01% of CVA Family Office's portfolio in Q1 2026, its #1674 holding.
CVA Family Office first reported a position in Veracyte in Q2 2024 and has held it in 8 quarters since.
CVA Family Office's Veracyte position peaked at $1.01K in Q4 2025.
334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on CVA Family Office's 13F filing for Q1 2026, filed 29 Apr 2026.